Tempus AI (NASDAQ:TEM) Shares Rise 5.3% - What Lies Ahead?

Tempus AI, Inc. (NASDAQ:TEM) experienced an upswing of 5.3% in trading on Monday, reaching a peak price of $59.80 before last settling at $60.40. During the day, a total of 6,700,130 shares exchanged hands, indicating a 34% decrease in volume compared to the average trading volume of 10,095,790 shares. The stock's previous closing price was $57.39.

Wall Street Analysts Predict Growth

Major financial institutions have recently analyzed Tempus AI’s performance. Stifel Nicolaus downgraded the stock from a "buy" to a "hold" rating while raising their price target from $45.00 to $65.00 on November 11th. On November 12th, Piper Sandler reaffirmed a "neutral" rating, increasing their price target to $70.00, up from $40.00. Loop Capital adjusted their target price downward from $57.00 to $52.00, also assigning a "buy" rating. Additionally, Bank of America raised their price target from $52.00 to $54.00 while maintaining a "neutral" outlook on the stock. Wolfe Research introduced their coverage of Tempus AI on December 13th and assigned an "outperform" rating with a target price of $60.00. In summary, three analysts have given the stock a hold rating, while nine others have rated it as a buy. According to MarketBeat, the average rating is "Moderate Buy" with an average target price of $56.36.

Tempus AI Stock Performance Overview

The company's 50-day simple moving average stands at $44.18, while the 200-day simple moving average is at $48.29. Tempus AI shows a debt-to-equity ratio of 8.17, a quick ratio of 2.55, and a current ratio of 2.69.

Insider Trading Activities

In recent insider news, Chief Accounting Officer Ryan M. Bartolucci sold 13,770 shares on January 31st for an average price of $60.00, totaling $826,200.00. Following this sale, he now holds 57,237 shares valued at approximately $3,434,220, representing a 19.39% decrease in his position. Additionally, Director David R. Epstein sold 620 shares on December 11th at an average price of $41.81, worth $25,922.20, reflecting a 2.17% decrease in his holdings. Over the past ninety days, insiders have sold 2,037,702 shares valued at $89,449,651.

Institutional Investment in Tempus AI

Several institutional investors have adjusted their positions in Tempus AI. Sumitomo Mitsui Trust Group Inc. boosted their holdings by 166.0% in the fourth quarter, now owning 3,239,093 shares worth $109,352,000 after acquiring an additional 2,021,394 shares. ARK Investment Management LLC increased its stake by 355.0% in the third quarter, now holding 2,378,157 shares valued at $134,604,000. NEA Management Company LLC also expanded its holdings by 17.8%, owning 5,385,979 shares worth $304,846,000 following an additional purchase of 813,169 shares. Millenium Management LLC had entered a new stake valued at about $8,067,000 in the second quarter, joined by the Healthcare of Ontario Pension Plan Trust Fund, which initiated its position worth about $5,250,000. Currently, institutional investors and hedge funds represent 24.22% of the stock's ownership.

About Tempus AI

Tempus AI Inc is a pioneering technology firm focused on enhancing precision medicine through advanced applications of artificial intelligence, primarily within the healthcare sector. The company provides AI-supported precision medicine solutions to healthcare providers to tailor patient treatment and simultaneously streamlines the discovery and delivery of optimal therapeutic options.

Is Tempus AI a Worthwhile Investment?

Before considering an investment in Tempus AI, prospective investors should take into account the insights provided by top market analysts regarding various stocks. Although Tempus AI has a "Moderate Buy" rating, analysts are recommending several stocks that they believe might be more promising investment opportunities.

Investing in stocks can be complex, and it is advisable to conduct thorough research or consult financial advisors before making investment decisions.

Tempus, Stock, Trading